Focus on: Overactive Bladder for Advanced Practice Providers

New for 2026, Focus on: are a series of accredited sessions offering an in-depth exploration of key clinical topics aligned with AUA’s ongoing needs assessments. This session provides a deeper dive into updating APPs on the latest advancements in the management of patients with OAB, specifically OAB associated with Benign Prostatic Hyperplasia (BPH), counseling patients on their condition and applying emerging evidence into clinical decision-making.

Learning Objectives:
After participating in this CME activity, participants will be able to:
1. Differentiate symptoms and potential pharmacological treatments for men with OAB and OAB plus BPH.
2. Counsel patients on their condition and treatment options available including expected benefits and risks of treatments.
3. Implement pharmacologic OAB treatment strategies in patients with and without BPH based on efficacy, safety, and patient expectations.
4. Integrate patient-centered pharmacological treatment of OAB based on mechanisms of action, side effects, and contraindications.
5. Evaluate and apply emerging evidence of the association of antimuscarinic medications with cognitive decline, including long-term use and use in frail patients with OAB, into clinical decision-making.